Improving the efficiency of the development of drugs for stroke

David W. Howells, Emily S. Sena, Victoria O'Collins, Malcolm R. Macleod

The mortality and morbidity associated with stroke makes the development of new drugs a research priority. Unsuccessful clinical trials have dampened enthusiasm for the development of neuroprotective drugs. The article Improving the efficiency of the development of drugs for stroke published as in the Translational research edition of the international Journal of stroke use empirical evidence derived from systematic reviews of stroke drug development to identify stages of drug development which might be improved and proposes helpful exemplar strategies and basic economic modeling assessing the impact of these strategies.

Carmen Lahiff-Jenkins Managing Editor of the International Journal of Stroke spoke to Assoc. Professor David Howells from The Florey Institute of Neurosciences and Mental Health.